Arbormed

Arbormed is a biopharmaceutical company founded in 2017 with a focus on developing and commercializing therapeutics for diseases with high unmet medical needs and untapped market opportunities. The company operates in South Korea and the US, utilizing resources efficiently to enable fast pipeline development and US market entry. Arbormed's Demand-Driven Development (D³) approach incorporates three strategic pillars to build a risk-balanced pipeline. These include innovative new drug development, focusing on rare diseases, and the commercialization of complex generics with limited competition in the US, developed by Korean companies. Arbormed's slogan, "Diversified & balanced drug development & commercialization company with operations in S. Korea and USA," reflects its commitment to a diversified and balanced approach in the biopharma and pharmaceutical industries. The company's focus on rare diseases and complex generics presents a unique opportunity for investors interested in the biopharmaceutical sector. Overall, Arbormed's strategic approach and operations in both South Korea and the US position the company as an attractive investment opportunity in the biopharmaceutical industry.